NUVB · Nuvation Bio Inc.
$6.43
+0.17 (+2.72%)
At close · Jul 21
Market Cap
$2.24B
Shares
348.20M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$62.9M
+699%
FY2025
Net Income
-$204.63M
+64%
FY2025
Gross Margin
10.1%
FY2024
Operating Margin
-338.72%
+7188.6pp
FY2025
Diluted EPS
-$0.60
+71.6%
FY2025
Operating Cash Flow
-$173.43M
-33%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $143.05M | $62.9M | $7.87M | $0 | — | — | — | |
| $12.24M | — | $7.08M | $0 | — | — | — | |
| $14.51M | — | $795K | $0 | — | — | — | |
| — | — | 10.1% | — | — | — | — | |
| $125.55M | $115.11M | $99.12M | $71.29M | $87.82M | $69.04M | $32.6M | |
| $28.16M | — | — | $28.53M | $31.92M | $24.28M | $10.95M | |
| $154.48M | $151.56M | $69.23M | $28.53M | — | — | — | |
| — | $1.74M | $683K | $222K | $199K | $184K | $103K | |
| — | — | — | — | $7.4M | — | — | |
| $293.23M | $275.97M | $600.5M | $99.82M | $119.73M | $93.32M | $43.55M | |
| -$150.18M | -$213.06M | -$592.63M | -$99.82M | -$119.73M | -$93.32M | -$43.55M | |
| — | -338.72% | -7527.33% | — | — | — | — | |
| — | -$211.33M | -$591.94M | -$99.6M | -$119.54M | -$93.13M | -$43.45M | |
| $6.71M | $13.68M | $341K | $0 | — | — | — | |
| — | — | — | — | — | — | $7011 | |
| $4.19M | $8.44M | $24.69M | $24.02M | $15.54M | $6.47M | $1.89M | |
| -$145.99M | -$204.63M | -$567.94M | -$75.8M | -$104.2M | -$86.85M | -$41.66M | |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$145.99M | -$204.63M | -$567.94M | -$75.8M | -$104.2M | -$86.85M | -$41.66M | |
| — | -325.31% | -7213.76% | — | — | — | — | |
| -$148.22M | -$205.39M | -$567.55M | -$70.1M | -$108.54M | -$89.59M | -$40.52M | |
| USD/shares | — | -$0.60 | -$2.11 | -$0.35 | -$0.48 | -$0.44 | — |
| USD/shares | — | -$0.60 | -$2.11 | -$0.35 | -$0.48 | -$0.44 | — |
| shares | — | 341.54K | 268.77K | 218.88K | 216.72K | 197.89K | 97.53M |
| shares | — | 341.54K | 268.77K | 218.88K | 216.72K | 197.89K | 97.53M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.03×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Japan | $28,829,000 | $2,726,000 |
| United States | $24,663,000 | $0 |
| China | $9,410,000 | $5,147,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| License | $38,239,000 | $7,873,000 |
| Product Revenue | $24,700,000 | — |
| Product | $24,663,000 | $0 |
Key facts
CIK
1811063
CUSIP
67080N101
13F (30d)
18 filings
18 filers
Visit website
Investor relations